About the Authors

Rodrigo B. Mansur

rodrigomansur71@uol.com.br

Affiliations National Institute of Developmental Psychiatry for Children and Adolescents, CNPq, São Paulo, Brazil, Interdisciplinary Lab for Clinical Neurosciences (LiNC), Universidade Federal de Sao Paulo (UNIFESP), Sao Paulo, Brazil, Mood Disorders Psychopharmacology Unit (MDPU), University Health Network, University of Toronto, Toronto, Canada

Graccielle R. Cunha

Affiliations National Institute of Developmental Psychiatry for Children and Adolescents, CNPq, São Paulo, Brazil, Interdisciplinary Lab for Clinical Neurosciences (LiNC), Universidade Federal de Sao Paulo (UNIFESP), Sao Paulo, Brazil

Elson Asevedo

Affiliations National Institute of Developmental Psychiatry for Children and Adolescents, CNPq, São Paulo, Brazil, Interdisciplinary Lab for Clinical Neurosciences (LiNC), Universidade Federal de Sao Paulo (UNIFESP), Sao Paulo, Brazil

André Zugman

Affiliations National Institute of Developmental Psychiatry for Children and Adolescents, CNPq, São Paulo, Brazil, Interdisciplinary Lab for Clinical Neurosciences (LiNC), Universidade Federal de Sao Paulo (UNIFESP), Sao Paulo, Brazil

Maiara Zeni-Graiff

Affiliation Interdisciplinary Lab for Clinical Neurosciences (LiNC), Universidade Federal de Sao Paulo (UNIFESP), Sao Paulo, Brazil

Adiel C. Rios

Affiliation Interdisciplinary Lab for Clinical Neurosciences (LiNC), Universidade Federal de Sao Paulo (UNIFESP), Sao Paulo, Brazil

Sumit Sethi

Affiliation Interdisciplinary Lab for Clinical Neurosciences (LiNC), Universidade Federal de Sao Paulo (UNIFESP), Sao Paulo, Brazil

Pawan K. Maurya

Affiliation Interdisciplinary Lab for Clinical Neurosciences (LiNC), Universidade Federal de Sao Paulo (UNIFESP), Sao Paulo, Brazil

Mateus L. Levandowski

Affiliations National Institute of Developmental Psychiatry for Children and Adolescents, CNPq, São Paulo, Brazil, Institute of Biomedical Research, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil

Ary Gadelha

Affiliations National Institute of Developmental Psychiatry for Children and Adolescents, CNPq, São Paulo, Brazil, Interdisciplinary Lab for Clinical Neurosciences (LiNC), Universidade Federal de Sao Paulo (UNIFESP), Sao Paulo, Brazil

Pedro M. Pan

Affiliations National Institute of Developmental Psychiatry for Children and Adolescents, CNPq, São Paulo, Brazil, Interdisciplinary Lab for Clinical Neurosciences (LiNC), Universidade Federal de Sao Paulo (UNIFESP), Sao Paulo, Brazil

Laura Stertz

Affiliations National Institute of Developmental Psychiatry for Children and Adolescents, CNPq, São Paulo, Brazil, Department of Psychiatry, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, Center for Translational Psychiatry, Department of Psychiatry and Behavioral Sciences, The University of Texas Health Science Center at Houston, Houston, United States of America

Síntia I. Belangero

Affiliations National Institute of Developmental Psychiatry for Children and Adolescents, CNPq, São Paulo, Brazil, Interdisciplinary Lab for Clinical Neurosciences (LiNC), Universidade Federal de Sao Paulo (UNIFESP), Sao Paulo, Brazil

Márcia Kauer-Sant' Anna

Affiliations National Institute of Developmental Psychiatry for Children and Adolescents, CNPq, São Paulo, Brazil, Department of Psychiatry, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

Antônio L. Teixeira

Affiliations National Institute of Developmental Psychiatry for Children and Adolescents, CNPq, São Paulo, Brazil, Interdisciplinary Laboratory of Medical Investigation, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil

Jair J. Mari

Affiliations National Institute of Developmental Psychiatry for Children and Adolescents, CNPq, São Paulo, Brazil, Interdisciplinary Lab for Clinical Neurosciences (LiNC), Universidade Federal de Sao Paulo (UNIFESP), Sao Paulo, Brazil

Luis A. Rohde

Affiliations National Institute of Developmental Psychiatry for Children and Adolescents, CNPq, São Paulo, Brazil, Department of Psychiatry, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

Euripedes C. Miguel

Affiliations National Institute of Developmental Psychiatry for Children and Adolescents, CNPq, São Paulo, Brazil, Department of Psychiatry, Universidade de Sao Paulo, Sao Paulo, Brazil

Roger S. McIntyre

Affiliation Mood Disorders Psychopharmacology Unit (MDPU), University Health Network, University of Toronto, Toronto, Canada

Rodrigo Grassi-Oliveira

Affiliations National Institute of Developmental Psychiatry for Children and Adolescents, CNPq, São Paulo, Brazil, Institute of Biomedical Research, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil

Rodrigo A. Bressan

Affiliations National Institute of Developmental Psychiatry for Children and Adolescents, CNPq, São Paulo, Brazil, Interdisciplinary Lab for Clinical Neurosciences (LiNC), Universidade Federal de Sao Paulo (UNIFESP), Sao Paulo, Brazil

Elisa Brietzke

Affiliations National Institute of Developmental Psychiatry for Children and Adolescents, CNPq, São Paulo, Brazil, Interdisciplinary Lab for Clinical Neurosciences (LiNC), Universidade Federal de Sao Paulo (UNIFESP), Sao Paulo, Brazil

Competing Interests

Dr. Mansur has received support from FAPESP, Brazil and fellowship funding from Lundbeck, Canada. Dr. Pan has received payment for development of educational material for Janssen-Cilag and AstraZeneca and has received meeting payment expenses from Eli Lilly and Co. Dr. Gadelha has received support from CNPq, Brazil, and has served on the speakers’ bureau and the advisory board for Janssen-Cilag. Dr. McIntyre, has served as an adviser or consultant for AstraZeneca, Bristol-Myers Squibb, Lilly, GlaxoSmithKline, Janssen-Ortho, Lundbeck, Merck & Co., Organon, Pfizer and Shire; has served as a speaker or a member of a speakers bureau for AstraZeneca, Lilly, Janssen-Ortho, Lundbeck, Merck & Co. and Pfizer; and has received grants for clinical research from AstraZeneca, Lilly, Janssen-Ortho, Lundbeck, Pfizer and Shire. Dr. Rohde has served as a consultant to, on the speakers’ bureau for, and/or on the advisory board for Eli Lilly and Co., Janssen-Cilag, Novartis, and Shire. He has received royalties from Artes Médicas and Oxford University Press. He has also chaired the Attention Deficit Hyperactivity Disorder and Juvenile Bipolar Disorder Outpatient Programs, which have received unrestricted educational and research support from Eli Lilly and Co., Janssen-Cilag, Novartis, and Shire. Dr. Bressan has received honoraria and/or consultation fees from AstraZeneca, Janssen-Cilag, and Lundbeck and has received research funding from Janssen-Cilag, Eli Lilly and Co., Lundbeck, Novartis, and Roche. He has been a shareholder of Biomolecular Technology Ltd. He is affiliated with the Schizophrenia Program at Federal University of São Paulo, which has received unrestricted educational and research support from the following pharmaceutical companies in the last three years: Janssen-Cilag, Novartis, and Lundbeck. Dr. Brietzke has received support from CNPq, FAPESP, and CAPES, Brazil, as well as and from L’Oeal/UNESCO/Brazilian Academy of Sciences for Women in Science Fellowship and has served as an adviser of Janssen-Cilag. Dr. Cunha, Dr. Asevedo, Dr. Zugman, Dr. Zeni-Graff, Dr. Rios, Dr. Sethi, Dr. Maurya, Dr. Levandowski, Dr. Stertz, Dr. Belangero, Dr. Kauer- Sant' Anna, Dr. Teixeira, Dr. Mari, Dr. Miguel and Dr. Grassi-Oliveira report no biomedical financial interests or potential conflicts of interests. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.

Author Contributions

Conceived and designed the experiments: LAR ECM RAB EB. Performed the experiments: RBM GRC EA AZ MZG ACR SS PKM MLL AG PMP. Analyzed the data: RBM GRC EA AZ EB. Contributed reagents/materials/analysis tools: LS SIB MKS ALT. Wrote the paper: RBM GRC EA AZ JJM LAR ECM RSM RGO RAB EB.